Latest Conference Articles

According to data presented at the Association for Research in Vision and Ophthalmology annual meeting in New Orleans, composite efficacy data validate MCO-010 as a potential treatment for RP.

D-4517.2 is a novel precision nanomedicine that inhibits neovascularization by targeting activated microglia and hypertrophic retinal pigment cells, cells responsible for the increased vascularization associated with neovascular age-related macular degeneration (wet AMD) and diabetic macular edema (DME).

According to Clearside Biomedical, the suprachoroidal delivery of small molecule suspensions demonstrated targeted, compartmentalized and durable drug delivery.

Belite Bio Inc. presented 18-month data from its ongoing two-year, open-label Phase 2 clinical study of LBS-008 (Tinlarebant), a novel oral therapy intended to reduce the accumulation of toxins in the eye that cause STGD1 and contribute to GA.

Ophthalmology Times® talked with Bruce Ksander, PhD, about epigenetic reprogramming to reverse aging and restore function to retinal ganglion cells at this year's ARVO meeting.

Ophthalmology Times® talked with Steven Carrubba, MD, about monkeypox skin disease and eye disease in patients who were immunocompromised in New York at this year's ARVO meeting.

Genentech announced post-hoc data indicating treatment with faricimab-svoa (Vabysmo) led to greater and faster drying of retinal fluid with fewer injections for the treatments of wet AMD and DME, when compared to aflibercept.

Ophthalmology Times® talked with David Tanzer, MD, about OcuTerra Therapeutics and their development of OTT166 in the treatment of diabetic retinopathy.

According to the company, consistent clinical efficacy across multiple signs and symptoms of dry eye along with excellent safety and tolerability build a differentiating product profile.

In a presentation at ARVO 2023 in New Orleans, Yuyu Pharma’s YP-P10 is a novel, patented, synthetic peptide with anti-inflammatory properties being explored for the potential treatment of dry eye disease.

The company shared data at the Association for Research in Vision and Ophthalmology annual meeting in New Orleans that demonstrated OpRegen surgical bleb coverage of areas of GA may be critical for optimizing patient outcomes.

VLTR-557, Valitor's long-acting anti-VEGF biologic in development for durable wet age-related macular degeneration (AMD) treatment, showed that a single intravitreal (ITV) injection has potential to maintain clinical efficacy for more than six months.

Ophthalmology Times® talked with Christine Kay, MD, about the treatment of GUCY2D associated Leber congenital amaurosis type 1 at this year's ARVO meeting.

Ronald Zambrano, lab supervisor for the advanced Ophthalmic Imaging Lab at NYU Langone, talks about lamina cribrosa pressure and predicting structural glaucoma progression at this year's ARVO meeting.

Ophthalmology Times® talked with Penny Asbell, MD, FACS, MBA, about the ARMOR study and antibiotic resistance at this year's ARVO meeting.

Atsena Therapeutics announced positive 6-month safety and efficacy data from the ongoing Phase I/II clinical trial of ATSN-101, a gene therapy for the treatment of GUCY2D-associated Leber congenital amaurosis (LCA1).

Ophthalmology Times® talked with Ronald Zambrano, lab supervisor for the advanced Ophthalmic Imaging Lab at NYU Langone about lamina cribrosa pressure and predicting structural glaucoma progression at this year's ARVO meeting.

Post-hoc analyses from four Phase III studies indicate Vabysmo dried retinal fluid faster with fewer injections in wet age-related macular degeneration and diabetic macular edema.

Dr Edmund Arthur shares his research on the early detection of diabetic retinopathy in underserved communities at this year's ARVO meeting.

Ophthalmology Times® talked with Roger Goldberg, MD, MBA, about macular leakage area in the YOSEMITE and RHINE trials comparing faricimab to aflibercept at this year's ARVO meeting.

Instead, vitamins C and E may actually be associated with a slightly increased risk of DED.

Ophthalmology Times® spoke with Carl Danzig, MD, FASRS, at the 2023 ARVO annual meeting to learn more about the post hoc analysis for the GATHER trials and the new data on the correlation between vision loss and GA growth.

Ophthalmology Times® talked with Edmund Arthur, OD, PhD, FAAO, about his research on the early detection of diabetic retinopathy in underserved communities at this year's ARVO meeting.

Body mass index (BMI), central obesity, and the metabolic syndrome may be deciding risk factors in glaucoma.

Ophthalmology Times® talked with Jay Barth, MD, about the work at Ascidian Therapeutics and their research into developing a new way to administer gene therapy at this year's ARVO meeting.

In a presentation at the Association for Research in Vision and Ophthalmology annual meeting in New Orleans, it was noted ATSN-101 demonstrated clinically meaningful improvements in vision at the highest dose with no drug-related serious adverse events 6 months post-treatment.

In a presentation at the Association for Research in Vision and Ophthalmology annual meeting in New Orleans, SB15 demonstrates comparable efficacy, safety, immunogenicity, and pharmacokinetics profiles to reference aflibercept up to Week 56.